Kurser indlæses...

Prognose

Vi har ingen analytikerdata for denne virksomhed.

Nyheder Til nyhedsfeedet

Evolv expands partnership with Gillette Stadium and becomes official provider for fan security screening

Evolv has renewed and expanded its partnership with Gillette Stadium, which began in 2021, so that KI-supported Evolv Express security lanes will be installed at additional entrances. The systems are designed to detect concealed weapons at normal walking speed and have already screened more than seven million visitors at the stadium. The contract extension strengthens Evolv’s presence in the greater Boston area; the company reports 36.6% revenue growth last year, Q2 revenue of $32.5 million (+29%) and remains unprofitable despite strong demand (negative EBITDA). Analyst reactions raised price targets and ratings but highlighted the still-present valuation premium. » Mere på de.investing.com
Evolv Technologies reaches new 52-week high at $7.45

Shares of Evolv Technologies Holdings Inc. rose to a new 52-week high of $7.45 after the stock gained about 143.77% over the past year. The company reported revenue growth of 36.71%, a positive EBITDA in the first quarter, a $75 million credit facility from MidCap Financial and a $19.36 million school contract with Gwinnett Schools; analyst price targets range from $5.50 to $8.25. Positive analyst revisions (Northland, Craig-Hallum, Lake Street) and the resolution of an FTC probe are cited as drivers of the optimistic sentiment. » Mere på de.investing.com
Evolv Technologies reaches new 52-week high after strong growth and positive analyst ratings

Evolv Technologies' stock climbed to a 52-week high of $7.10, supported by revenue growth of 36.71% and strong performance over the past year. The company also secured a $75 million credit facility to strengthen its subscription-based business and significantly exceeded revenue expectations in the first quarter. Analysts upgraded the stock to 'Outperform' or 'Buy' due to improved financial metrics and strategic initiatives. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde EVOLVA N en omsætning på 0 € og et nettoresultat på -688,15 t €

(EUR)	juni 2026	YoY
Omsætning	0	-
Bruttofortjeneste	0	-
Nettoresultat	-688,15 t	-
EBITDA	-839,6 t	-

Fundamentale data

Nøgletal	Værdi
Markedsværdi	17,38 mio. €
Antal aktier	7,21 mio.
Højeste/laveste i 52 uger	22,44 € - 0,67 €
Udbytte	Nej
Beta	-0,05
P/E (PE Ratio)	-17,67
PEG (PEG Ratio)	0,59
K/I (PB Ratio)	3,08
P/S (PS Ratio)	0,00

Virksomhedsprofil

Evolva Holding SA opdager, forsker i, udvikler og kommercialiserer naturbaserede ingredienser til brug i smags- og duftstoffer, sundhedsingredienser, sundhedsbeskyttelse og andre sektorer i Schweiz, USA og internationalt. Virksomheden tilbyder forskellige ingredienser, herunder Veri-te Resveratrol, en naturligt fremstillet polyphenol, der forekommer naturligt i druer og andre planter, herunder jordnødder, tranebær og bær; L-Arabinose, et smagsstof, der anvendes i Maillard-reaktionen; Valencen, en aromakomponent i citrusfrugter og citrusafledte odorstoffer; Nootkatone, en aromaingrediens i grapefrugt, som fremstilles ved biokemisk oxidation af valencen; og Vanillin, en primær komponent i vaniljeekstrakt. Virksomheden blev grundlagt i 2004 og har hovedkontor i Reinach, Schweiz.